ULTRAVIST 300 Drug Patent Profile

When do Ultravist 300 patents expire, and what generic alternatives are available?

Ultravist 300 is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in ULTRAVIST 300 is iopromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopromide profile page.

Summary for ULTRAVIST 300

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	11
Patent Applications:	2,584
DailyMed Link:	ULTRAVIST 300 at DailyMed

Recent Clinical Trials for ULTRAVIST 300

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Guerbet/Liebel-Flarsheim	Phase 4
Duke Clinical Research Institute	Phase 4
GE Healthcare	Phase 4

See all ULTRAVIST 300 clinical trials

Pharmacology for ULTRAVIST 300

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for ULTRAVIST 300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ULTRAVIST 300	iopromide	INJECTABLE;INJECTION	020220-002	May 10, 1995		RX	Yes	Yes
Bayer Hlthcare	ULTRAVIST 300 IN PLASTIC CONTAINER	iopromide	INJECTABLE;INJECTION	020220-005	Nov 18, 2008		DISCN	Yes	No

Expired US Patents for ULTRAVIST 300

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ULTRAVIST 300	iopromide	INJECTABLE;INJECTION	020220-002	May 10, 1995

International Patents for ULTRAVIST 300

See the table below for patents covering ULTRAVIST 300 around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	2909439
Yugoslavia	61780
Spain	491254
South Africa	8001350
Australia	529565
Finland	800696
Spain	489337

ULTRAVIST 300 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Ultravist 300

Overview of Ultravist 300

Ultravist 300 is a contrast medium used in diagnostic imaging, specifically for X-ray and Computed Tomography (CT) scans. The active ingredient is iopromide, and it is manufactured by Bayer Healthcare[1].

Market Position

Competitive Landscape

The contrast media market is highly competitive, with key players including Bayer AG, GE HealthCare, Guerbet, Lantheus Holdings, Inc., Bracco, and others. Ultravist 300, as part of Bayer's portfolio, competes in a market driven by the increasing demand for advanced diagnostic imaging and the rising prevalence of chronic diseases such as cancer and cardiovascular conditions[4].

Market Share and Segmentation

The X-ray/CT segment, where Ultravist 300 is primarily used, held the largest share of the Canada contrast media market in 2023, accounting for 64.4% of the market. This segment is expected to continue driving the market due to the high demand for CT scans and the need for high-quality contrast agents to enhance image clarity and diagnostic accuracy[4].

Financial Performance

Revenue and Sales Growth

Bayer's pharmaceutical division, which includes Ultravist 300, has shown stable growth despite challenges in other segments. In the Q3 2024 financial report, Bayer noted that the pharmaceuticals division saw a sales growth of 4% on a currency and portfolio-adjusted basis. This growth was partly driven by the performance of radiology products, which includes contrast media like Ultravist 300[3].

EBITDA Margin and Profitability

The EBITDA margin for Bayer's pharmaceutical division was 26.9% in the first nine months of 2024, slightly lower than the previous year due to factors such as product mix changes and growth investments. However, the division remains profitable, with ongoing efficiency measures and pricing strategies helping to balance the impact of these factors[3].

Market Trends and Drivers

Increasing Demand for Diagnostic Imaging

The demand for advanced diagnostic imaging is on the rise, driven by the increasing prevalence of chronic diseases and an aging population. This trend is expected to continue, driving the growth of the contrast media market, including products like Ultravist 300[4].

Technological Advancements

Technological advancements in diagnostic imaging, such as the introduction of new ultrasound systems and contrast agents, are also driving market growth. For instance, the approval of new ultrasound contrast agents and the educational collaborations between industry stakeholders are expected to enhance the understanding and use of these agents, including those related to products like Ultravist 300[4].

Regulatory Approvals and Compliance

Regulatory approvals play a crucial role in the market dynamics of contrast media. For example, Health Canada's approval of new contrast agents, such as the supplemental new drug application (sNDA) for DEFINITY (Perflutren Lipid Microsphere) for pediatric patients, indicates a favorable regulatory environment that can support the growth of products like Ultravist 300[4].

Challenges and Headwinds

Generic Pressure

Bayer's pharmaceutical division, including products like Ultravist 300, faces challenges from generic competition. For instance, Xarelto, another key product in Bayer's portfolio, is increasingly affected by the availability of generics in Europe and Canada. While Ultravist 300 is a prescription-only product and less likely to face immediate generic competition, the broader impact of generics on the pharmaceutical market can affect overall market dynamics[3].

Currency and Pricing Pressures

Currency fluctuations and pricing pressures can also impact the financial performance of Ultravist 300. FX headwinds have been noted in Bayer's financial reports, affecting profitability. Additionally, stringent pricing strategies and resource shifts are necessary to balance these unfavorable changes[3].

Future Outlook

Growth Projections

The Canada contrast media market, which includes Ultravist 300, is projected to grow at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2030, reaching USD 300.15 million by 2030. This growth is driven by the increasing demand for diagnostic imaging and the rising prevalence of chronic diseases[4].

Strategic Initiatives

Bayer is focusing on growth investments, new product launches, and strategic collaborations to maintain its market position. The company's emphasis on innovation, such as the introduction of new products like Acoramidis and Elinzanetant, and its strong launch execution across the portfolio, are expected to support the continued growth of its pharmaceutical division, including products like Ultravist 300[3].

Key Takeaways

• Market Position: Ultravist 300 is a key product in the competitive contrast media market, dominated by players like Bayer AG, GE HealthCare, and others.
• Financial Performance: The product contributes to Bayer's stable pharmaceutical division growth, despite challenges from generics and currency fluctuations.
• Market Trends: Increasing demand for diagnostic imaging, technological advancements, and favorable regulatory approvals drive market growth.
• Challenges: Generic pressure, currency fluctuations, and pricing pressures are significant challenges.
• Future Outlook: The market is projected to grow at a CAGR of 7.2% from 2024 to 2030, driven by increasing demand for diagnostic imaging.

FAQs

What is the active ingredient in Ultravist 300?

The active ingredient in Ultravist 300 is iopromide[1].

Which company manufactures Ultravist 300?

Ultravist 300 is manufactured by Bayer Healthcare[1].

What is the primary use of Ultravist 300?

Ultravist 300 is primarily used as a contrast medium for X-ray and Computed Tomography (CT) scans[1].

How is the contrast media market expected to grow?

The Canada contrast media market is expected to grow at a CAGR of 7.2% from 2024 to 2030, reaching USD 300.15 million by 2030[4].

What are the main drivers of the contrast media market?

The main drivers include the increasing demand for advanced diagnostic imaging, rising prevalence of chronic diseases, and a growing aging population[4].

Sources

1. Pharmacompass: Ultravist 300 | Drug Information, Uses, Side Effects, Chemistry
2. Patsnap Synapse: Iopromide - Drug Targets, Indications, Patents
3. Bayer: Q3 2024 2024-11-12 Presentation charts
4. Grandview Research: Canada Contrast Media Market Size & Share Report, 2030
5. Bayer: Half-Year Financial Report 2024 - Bayer AG